Table 4.

Effects of genetic determinants on risks for cholangiocarcinoma

Genotype		No. CCA (%)	No. control (%)	OR	95%CI		P value	Ref.	Ethnic group
					LL	UL
				Adjusted OR
CYP1A2, Male	*1F/*1F	85 (57.4)	88 (51.2)	1.0	Reference			Prawan et al[8] 2005	Thai
	*1A/*1F	59 (39.9)	69 (40.1)	0.9	0.55	1.47	0.677
	*1A/*1A	4 (2.7)	15 (8.7)	0.28	0.08	0.94	0.039
NAT2	All, except *6B, *7A and *13	193 (89.4)	162 (69.5)	1.0	Reference
	One or two alleles (All, except *6B, *7A and *13)	23 (10.6)	71 (30.5)	0.26	0.15	0.44	< 0.001
				Crude OR
GST01	A140/A140	13 (43.33)	26 (86.67)	1.0	Reference			Marahatta et al[9] 2006	Thai
	A140/D140 + D140/D140	17 (56.67)	4 (13.33)	0.86	2.07	37.85
		Minor allele frequency
	Alleles	PSC2 with CCA (n = 49)	PSC without CCA (n = 316)	OR			Corrected P
NKG2D1	rs11053781 (Intron 5) G vs A	0.66	0.49	2.08	1.31	3.29	0.011	Melum et al[12] 2008	Norwegian
	rs2617167 (Intron 1) A vs G	0.39	0.22	2.32	1.47	3.66	0.002
		PSC with CCA (n = 49)	Healthy controls (n = 368)
	rs11053781 (Intron 5) G vs A	0.66	0.5	1.95	1.23	3.07	0.021
	rs2617167 (Intron 1) A vs G	0.39	0.23	2.2	1.40	3.44	0.003
		Counts (frequencies) of alleles/genotypes
		2n = 120	2n = 146	Crude OR				Hoeblinger et al[13] 2009	Caucasian
MRP2/ABCC23	ABCC2 c.3972 C (exon 28, synonymous SNP)	73 (0.61)	108 (0.74)
	ABCC2 c.3972 T	47 (0.39)	38 (0.26)	1.83	1.087	3.08	0.022
				OR
MYH rs3219476	T/T	25 (42.4)	26 (26.0)	1.0	Reference			You et al[14] 2013	Han Chinese
	T/G	20 (33.9)	58 (58.0)	0.359	0.17	0.758	0.006
	G/G	14 (23.7)	16 (16.0)	0.91	0.369	2.246	0.838
	T/G + G/G	34 (57.6)	74 (74.0)	0.478	0.241	0.946	0.033
MYH rs3219472	G/G	28 (47.5)	46 (46.0)	1.0	Reference
	G/A	19 (32.2)	47 (47.0)	0.664	0.326	1.351	0.258
	A/A	12 (20.3)	7 (7.0)	2.816	0.992	7.999	0.047
	G/A + A/A	31 (52.5)	54 (54.0)	0.943	0.495	1.797	0.859

¹Natural killer cell receptor G2D;

²Primary sclerosing cholangitis;

³Multidrug resistance-associated protein 2 gene. OR: Odds ratio.